Cresco Labs Inc. (OTCMKTS:CRLBF – Get Free Report) has been assigned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating, two have given a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $2.50.
Several analysts have weighed in on the stock. Ventum Cap Mkts upgraded shares of Cresco Labs to a “strong-buy” rating in a research note on Friday, August 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cresco Labs in a research note on Monday, August 12th. Finally, Roth Capital raised shares of Cresco Labs from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 9th.
Get Our Latest Stock Analysis on Cresco Labs
Cresco Labs Price Performance
Cresco Labs (OTCMKTS:CRLBF – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.15). The company had revenue of $184.36 million during the quarter, compared to analyst estimates of $184.26 million. Cresco Labs had a negative net margin of 23.07% and a negative return on equity of 17.03%. As a group, sell-side analysts forecast that Cresco Labs will post -0.15 EPS for the current fiscal year.
Cresco Labs Company Profile
Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.
Read More
- Five stocks we like better than Cresco Labs
- How is Compound Interest Calculated?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Why is the Ex-Dividend Date Significant to Investors?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Cresco Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cresco Labs and related companies with MarketBeat.com's FREE daily email newsletter.